Search
for
Sort by
Research 181–210 of 1000+
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- JAK Inhibitors for Treatment of Alopecia Areata
- Topical Janus kinase inhibitors: A review of applications in dermatology
- Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
- Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
- Anti-inflammatory, cyclooxygenase inhibitory and antioxidant activities of standardized extracts of Tridax procumbens L.
- Topical Application of a Protein Kinase C Inhibitor Reduces Skin and Hair Pigmentation
- Trps1 activates a network of secreted Wnt inhibitors and transcription factors crucial to vibrissa follicle morphogenesis
- Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study
- Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- JAK inhibitors and alopecia areata
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling
- The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo
- Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane
- Specific Inhibition of Hair Follicle Formation by Epidermal Growth Factor in an Organ Culture of Developing Mouse Skin
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Selective non-steroidal inhibitors of 5α-reductase type 1
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Sulfatase inhibitors: a patent review
- Clinical application of 5α-reductase inhibitors
- JAK-inhibitors in dermatology: current evidence and future applications
- SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
- Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
- Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Allopregnanolone and Induction of Endogenous Opioid Inhibition of Oxytocin Responses to Immune Stress in Pregnant Rats
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata